Clinical Trials
49 trialsStudy of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors
Sotio Biotech Inc.
A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors
Seagen Inc.
A Phase 1 Study of [225Ac]-FPI-1434 Injection
Fusion Pharmaceuticals Inc.
T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers
National Institutes of Health Clinical Center (CC)
Study of BDC-3042 as Single Agent and in Combination With Cemiplimab in Patients With Advanced Malignancies
Bolt Biotherapeutics, Inc.
A Study of FAZ053 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies.
Novartis
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors
Nuvation Bio Inc.
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
Numab Therapeutics AG
A Study to Investigate LYL797 in Adults With Solid Tumors
Lyell Immunopharma, Inc.
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Study of Safety and Efficacy of Novel Immunotherapy Combinations in Patients With Triple Negative Breast Cancer (TNBC).
Novartis
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
Novartis
Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC
Pfizer
Study of ADCT-301 in Patients With Selected Advanced Solid Tumors
ADC Therapeutics S.A.
Neoantigen DNA Vaccine Alone vs. Neoantigen DNA Vaccine Plus Durvalumab in Triple Negative Breast Cancer Patients Following Standard of Care Therapy
Washington University School of Medicine
Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101)
Exelixis
A Study of PY314 in Subjects With Advanced Solid Tumors
Ikena Oncology
A Study of CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers
Gilead Sciences
A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies
Atreca, Inc.
RBX7455 Before Surgery for the Treatment of Operable Breast Cancer
Mayo Clinic
FT516 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
FT538 in Combination With Monoclonal Antibodies in Advanced Solid Tumors
Fate Therapeutics
Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted
Jonsson Comprehensive Cancer Center
Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors
Oncorus, Inc.
A Study of TAK-659 in Combination With Nivolumab in Participants With Advanced Solid Tumors
Calithera Biosciences, Inc
Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
National Cancer Institute (NCI)
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
M.D. Anderson Cancer Center
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
GB1275 Monotherapy and in Combination With an Anti-PD1 Antibody in Patients With Specified Advanced Solid Tumors or in Combination With Standard of Care in Patients With Metastatic Pancreatic Adenocarcinoma
Gossamer Bio Inc.
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
Zai Lab (Hong Kong), Ltd.
BN-Brachyury, Entinostat, Adotrastuzumab Emtansine and M7824 in Advanced Stage Breast Cancer (BrEAsT)
National Institutes of Health Clinical Center (CC)
A Study of LY3435151 in Participants With Solid Tumors
Eli Lilly and Company
MK-8628-006
Merck Sharp & Dohme LLC
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer
Hoffmann-La Roche
Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole
ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)
A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors
Eli Lilly and Company
PF-06671008 Dose Escalation Study in Advanced Solid Tumors
Pfizer
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
DHEA in Treating Women Undergoing Surgery for Stage I, Stage II, or Stage III Breast Cancer
Barbara Ann Karmanos Cancer Institute
A Study Of PF-06647263 In Patients With Advanced Solid Tumors
Pfizer
A Dose Escalation Study of PF-06650808 in Patients With Advanced Solid Tumors
Pfizer
A Study of SC-005 in Subjects With Triple Negative Breast Cancer (TNBC)
AbbVie
A Study of Varlilumab and Atezolizumab in Patients With Advanced Cancer
Celldex Therapeutics
A Study Evaluating Safety and Pharmacokinetics of ABBV-221 in Subjects With Advanced Solid Tumor Types Likely to Exhibit Elevated Levels of Epidermal Growth Factor Receptor
AbbVie
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097, Paclitaxel, and Carboplatin Before Surgery in Treating Patients With Stage II or Stage III Triple-Negative Breast Cancer
National Cancer Institute (NCI)
RO4929097 and Vismodegib in Treating Patients With Breast Cancer That is Metastatic or Cannot Be Removed By Surgery
National Cancer Institute (NCI)
A Clinical Trial Comparing Gemcitabine and Carboplatin With and Without P276-00 in Subjects With Metastatic Triple Negative Breast Cancer, With a Run-in of Escalating Dose of P276-00 Added to Gemcitabine and Carboplatin
Piramal Enterprises Limited